Company News


Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company"), through its medical face mask manufacturing subsidiary, Micron Technologies Inc. ("Micron Technologies"), sympathizes with the worldwide wave of the Omicron Covid variant and urges its clients to utilize medical grade face masks in any social settings.

Corporate Video:

https://cdn.shopify.com/s/files/1/0492/9627/7672/files/Micron-Commercial.mp4?v=1641791344

Products

Micron Technologies has been operating at its facility in Delta, British Columbia, since August 2020, where it manufactures medical grade face masks under its Medical Device Establishment License issued by Health Canada. Micron Technologies is also registered with the US Food and Drug Administration. The Company's product line focuses on three key product lines:

  1. three ply medical grade face masks, which conform to ASTM F2100 Medical Grade Level 3 standards;
  1. N95 Model 8800 face masks, which have been approved by Health Canada and the US Food and Drug Administration; and
  1. face mask filters.

Available on Amazon, Shopify, and at Walmart

Micron Technologies' three-ply medical grade face masks and N95 Model 8800 face masks are available for purchase on Amazon, Shopify, and at Walmart. Face masks can also be purchased directly from Micron Technologies at https://micronti.com/pages/micron-video

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, British Columbia. The Company, through its subsidiary Micron Technologies, manufactures medical grade face masks. The Company also has an investment in digital telehealth platform in Kayan Health. Kayan Health is an artificial-intelligence powered health communications platform that allows doctors to communicate with their patients and monitor them remotely. https://kayanhealth.com

Kal Malhi, CEO
604-805-4602
kal@bullruncapital.ca

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109477

News Provided by Newsfile via QuoteMedia

DOCT:CNX
Beyond Medical Technologies

Beyond Medical Technologies


Keep reading...Show less
Beyond Medical Provides Corporate Update

Beyond Medical Provides Corporate Update

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") is pleased to provide a corporate update on its medical face mask manufacturing subsidiary Micron Technologies Inc. ("Micron Technologies").

The Company is reviewing Micron Technologies' medical face mask manufacturing business as many jurisdictions have recently lifted mask mandates and as demand for face masks rapidly declines. The Company is considering operating Micron Technologies' facility at reduced capacity or potentially terminating its mask manufacturing business via a sale of all inventory and equipment related to its mask manufacturing business and to seek new business opportunities.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Beyond Medical Technologies Announces Marketing Initiatives

Beyond Medical Technologies Announces Marketing Initiatives

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to announce that it has entered into an online marketing agreement ("AGORA Agreement") with AGORA Internet Relations Corp. ("AGORA") and an investor marketing agreement (the "INN Agreement") with Dig Media Inc.® dba as Investing News Network® ("INN").

AGORA Internet Relations Corp.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Beyond Medical Subsidiary Micron Technologies Achieves "Amazon's Choice" Designation and Begins to Accept Bitcoin Payments for its Made in Canada Face Masks

Beyond Medical Subsidiary Micron Technologies Achieves "Amazon's Choice" Designation and Begins to Accept Bitcoin Payments for its Made in Canada Face Masks

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies ").

Taking Healthcare Beyond Traditional Platforms (CNW Group/Beyond Medical Technologies Inc.)

"Amazon's Choice" Designation for Medical Grade Face Masks

Micron Technologies has been operating at the Company's facility in Delta, British Columbia since August 2020 where it manufactures three-ply medical grade face masks. In early April 2021 , Micron Technologies' three-ply medical grade face masks achieved the "Amazon's Choice" designation from Amazon. The "Amazon's Choice" designation is achieved by having a high star rating, competitive price, low return rate, consistent inventory, and high sales. Micron Technologies anticipates a sales boost following achieving the "Amazon's Choice" designation.

In addition to Amazon, Micron Technologies' products are available online at Walmart and Shopify. Institutional customers and those who are interested in obtaining a quote for large size orders are encouraged to contact Milan@micronti.com .

Micron Technologies Accepting Bitcoin

Micron Technologies has entered the cryptocurrency space by now accepting Bitcoin as a form of payment for its products. The option to pay with Bitcoin is available to both retail and wholesale customers. Customers who wish to pay with Bitcoin can do so on Micron Technologies' website where the payment will be completed via BitPay, a Bitcoin service provider.

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, British Columbia . The Company is developing its Organivore and Pharmavore waste digesters using its proprietary technology.

The Company, through its subsidiary Micron Technologies, is also manufacturing medical grade face masks.

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE Beyond Medical Technologies Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2021/27/c4406.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Beyond Medical Manufactures N95 Medical Face Masks as Third Wave of COVID-19 Surges

Beyond Medical Manufactures N95 Medical Face Masks as Third Wave of COVID-19 Surges

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies ").

Taking Healthcare Beyond Traditional Platforms (CNW Group/Beyond Medical Technologies Inc.)

Manufacturing Three-Ply Medical Grade Face Masks at Full Capacity

Micron Technologies has been manufacturing and selling three-ply medical grade face masks at the Company's facility in Delta, British Columbia since August 2020 . The three-ply medical grade face masks are being manufactured pursuant to Micron Technologies' Medical Device Establishment License issued by Health Canada. The three-ply medical grade face masks offer three layers of protection, which conforms to the American Society for Testing and Materials' F2100 Level 3 standards. The non-woven masks feature an adjustable nose clip designed to protect both front-line workers and consumers. Micron Technologies is currently operating three shifts a day to manufacture three-ply medical grade face masks.

Manufacturing N95 Face Masks

Micron Technologies is now also setting up manufacturing N95 Model 8800 face masks, which have been approved.  Micron Technologies has submitted its N95 Model 8800 face masks to the National Institute for Occupational Safety and Health (" NIOSH ") and is confident it will obtain NIOSH certification as its N95 Model 8800 face masks have already passed testing with Kinetrics Analytical and Environmental Laboratories. Micron Technologies has purchased a large quantity of raw materials to manufacture N95 Model 8800 face masks and plans to maximize production efforts once NIOSH certification has been obtained. As of last month there was still a significant shortage of N95 masks and approximately " 56 percent of frontline workers say they still don't have enough N95 masks. "

Third Wave of COVID-19

According to Dr. Abdu Sharkawy , an infectious disease specialist, the third wave of COVID-19 is " likely going to be worse than the first two ." With respect to the addition of variants, Dr. Sharkawy noted " and of course we've seen what these variants can offer, they can really lead to an explosion of cases very quickly ."  Dr. Theresa Tam , Canada's Chief Public Health Officer, announced a 64% increase in new cases involving variants. In addition to the new variants, the slow vaccine roll-out and complacency with public health restrictions are contributing to the third wave.

Earlier this month Canada surpassed 1,000,000 confirmed COVID-19 cases since the beginning of the pandemic, with the provinces of Ontario , Quebec , and British Columbia being hit the hardest by the third wave.

Products Now Available at Walmart

As previously announced, Micron Technologies' three-ply medical grade face masks and N95 medical grade face masks have been approved for sale by Walmart. Micron Technologies expects its products to be available at www.walmart.com in the coming weeks.

In addition to Walmart, Micron Technologies' products are also available on Amazon and Shopify. Institutional customers and those who are interested in obtaining a quote for large size orders are encouraged to contact Milan@micronti.com . Customers can also make orders directly at https://micronti.com .

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, British Columbia . The Company is developing its Organivore and Pharmavore waste digesters using its proprietary technology. The Company, through its subsidiary Micron Technologies, is also manufacturing medical grade face masks.

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE Beyond Medical Technologies Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2021/07/c7788.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Beyond Medical subsidiary Micron Technologies begins Sales of Made in Canada Face Masks to Walmart

Beyond Medical subsidiary Micron Technologies begins Sales of Made in Canada Face Masks to Walmart

Beyond Medical Technologies Inc. (" Beyond Medical " or the " Company ") (CSE: DOCT) ( Frankfurt : 7FM4) is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. (" Micron Technologies ").

Taking Healthcare Beyond Traditional Platforms (CNW Group/Beyond Medical Technologies Inc.)

Products Now Available at Walmart

Micron Technologies' three-ply medical grade face masks and N95 medical grade face masks have been approved for sale by Walmart. Micron Technologies has completed the onboarding process and its products will be available at www.walmart.com by the beginning of April 2021 .

Kal Malhi , CEO of Beyond Medical states: "We are pleased to offer our products to loyal Walmart customers at competitive prices. The availability of our product with one of the largest retailers in the world will bring significant exposure to our made-in- Canada medical face mask brand.  Our recently completed capital raise will allow us to ramp up manufacturing to meet new demand from Walmart customers."

In addition to Walmart, Micron Technologies' products are also available on Amazon and Shopify. Institutional customers and those who are interested in obtaining a quote for large size orders are encouraged to contact Milan@micronti.com .

Three-Ply Medical Grade Face Masks

Micron Technologies has been manufacturing and selling three-ply medical grade face masks since August 2020 . The masks are available in the colour blue and black. The majority of Micron Technologies' sales have been to provincial governments; however, sales are also being completed online to various other customers. Micron Technologies is considering acquiring additional manufacturing equipment and hiring more personnel as it is currently operating at full capacity and continues to sell out of inventory.

N95 Face Masks

In addition to the three-ply medical grade face masks, Micron Technologies is also manufacturing N95 Model 8800 face masks. Micron Technologies' N95 Model 8800 face masks have been approved by Health Canada and the US Food and Drug Administration. Additionally, the N95 Model 8800 face masks have passed testing with Kinetrics Analytical and Environmental Laboratories. Accordingly, Micron Technologies is confident that its N95 Model 8800 face masks will obtain medical-grade certification from the National Institute for Occupational Safety and Health in the coming weeks.  There are currently a limited number of NIOSH approved medical face mask manufacturers and the demand for these masks in outpacing supply.

On February 2,2012 , Washington Post reported on N95 masks: "The initial shortage has eased, but there still aren't enough medical masks for health-care workers, let alone others. Demand for N95s is 500 to 1,000 percent higher than it was a year ago, said Megan Ranney , co-founder of Get Us PPE, which helps front-line workers obtain personal protective equipment."

Last month President Biden's chief medical advisor for Covid-19, Dr. Anthony Fauci , indicated that Americans may still be wearing masks in 2023, as mask-wearing has been critical in slowing down the spread Covid-19. N95 masks are the gold standard of personal protective equipment, particularly among healthcare professionals as they provide the highest level of protection for the user and those in close proximity. Beyond Medical hopes to have its N95 Model 8800 face masks certified as soon as possible in an effort to reduce the spread of Covid-19.

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, BC . The Company is developing its Organivore and Pharmavore waste digesters using its proprietary technology. The Company, through its subsidiary Micron Technologies, is also manufacturing medical grade face masks.

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

FORWARD LOOKING STATEMENTS:

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE Beyond Medical Technologies Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2021/30/c9088.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
two open palms hold a sphere representing the earth with water in the background

Sustainable Packaging: Increasing Demand for Natural Solutions

We only have one planet — and until recently we've done a poor job taking care of it.

The packaging industry is one of the sectors in which this is most evident. With a projected market size of US$1.13 trillion by 2030, it also represents one of the most significant sources of pollution in the world. Globally, we produce roughly 380 million tons of plastic per year. Single-use items such as grocery bags, bottles and packaging represent around 50 percent of that number.

To put this into context, the plastic waste produced by soft drink companies could cover 83 football fields a day, and the pollution footprint of packaging is at least as bad.

Keep reading...Show less
Billy Goat Brands CEO Tony Harris

Billy Goat Brands CEO Tony Harris: Venture Capital Supporting Sustainability

Billy Goat Brands CEO Tony Harris: Venture Capital Supporting Sustainabilityyoutu.be

Keep reading...Show less
Albert Labs

Albert Labs Granted Health Canada Licence

Albert Labs has been issued a Health Canada License enabling the possession, production, and delivery of psilocybin and other psychoactive controlled substances

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the "Company"), a research and drug development company using advanced culture technology to create pharmaceutical-quality medicines for mental health treatments, is pleased to report it has been granted a Health Canada License dated 05-05-2022 for its research and production facility in Burnaby, Canada . This approval permits the legal possession, production, assembly, sale, and delivery of psilocybin and other psychoactive controlled substances within the confines of the regulations governing controlled substances.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model is pleased to announce that UI Co-Founder Dr Alberto Sola will present at the May 27 to 29 event: From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine which will be held in Toronto, Canada from May 27 to 29, 2022 .

Universal Ibogaine Co Founder Dr. Alberto Sola to present at From Research to Reality: Global Summit on Psychedelic Assisted Therapies and Medicine (CNW Group/Universal Ibogaine Inc.)

The Research to Reality event is presented by the Mental Health Commission of Canada , the Center for Addiction and Mental Health ("CAMH") and the Canadian Center on Substance Abuse and Addiction.

The event will be attended by researchers, clinicians' policy makers including representatives from Health Canada the FDA and the Mexico Ministry of Health ("COFEPRIS").

Dr. Sola, is a co-founder of Universal Ibogaine and a member of the Board of Directors, and he is the founder of the Clear Sky Recovery ibogaine clinic operating in Cancun , Mexico.  Alberto is a global leader in ibogaine detox treatments. He will present his latest findings in a panel titled " Ibogaine Hydrochloride and Acute Opioid Detox ., which will take place on Saturday May 28 at 4:15 PM EST "

UI CEO Nick Karos noted: "The importance of this event cannot be overstated.  This is the first event of its kind to bring together academic researchers, real world technicians and government policy makers. We believe this event will be an important catalyst for the industry and a significant milestone for our company.  This event will create awareness at the highest levels of the incredible potential of ibogaine."

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model through a planned Canadian Clinical Trial (focused on opioid use disorder), and ultimately to utilize that protocol around the globe through planned future licensing agreements.  UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as "plans", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.
Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

Related Links
https://universalibogaine.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/universal-ibogaine-co-founder-dr-alberto-sola-to-present-at-upcoming-research-to-reality-conference-301547153.html

SOURCE Universal Ibogaine Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2022/13/c5432.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Albert Labs

Albert Labs' Pre-Clinical Analytical and Toxicological Research Supports Company's Forthcoming Studies

World-renowned scientists from the University of CESPU Health Sciences Department, Portugal are working in partnership with Albert Labs' expert team to conduct safety and toxicology studies, in preparation for KRN-101's use in Real World Evidence studies.

Albert Labs International Corp. (CSE: ABRT) (FSE: VB50) (the "Company"), a research and drug development company using advanced culture technology to create pharmaceutical quality medicines, based on the mycelia of Psilocybe, today released further details of their ongoing preclinical studies. These are currently being conducted at the University of Health Sciences, CESPU, Portugal . The partnership established between Albert Labs and CESPU, provides Albert Labs with preclinical drug assessment capabilities, both in vivo and in vitro. The current work programme provides essential data on Albert Labs' mycelium-based pharmaceutical products in support of clinical trials due to start later this year. The clinical programme will investigate the potential to treat cancer-related distress, an indication thought to affect approximately 15 million patients worldwide.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
NeonMind Biosciences

NeonMind Biosciences: Using Psychedelics as Treatment for Mental Health Disorders and Weight Management

NeonMind Biosciences (CSE:NEON,OTCQB:NMDBF,FRA:6UF) has launched its campaign on the Investing News Network's Life Science and Psychedelics channels.

NeonMind Biosciences (CSE:NEON,OTCQB:NMDBF,FRA:6UF) is a drug development and healthcare company pioneering innovative ways to bring transformational mental health treatments to market with a focus on psychedelics. The company aims to improve access to psychedelic treatments with two strategies:

  1. Establishing specialized mental health clinics that provide currently available treatments such as ketamine and esketamine and to provide other psychedelic treatments when approved.
  2. Focusing on drug development of novel psychedelic treatments focusing on their proprietary drug candidates to treat behavioral deficits in patients with weight management issues and obesity.

Medical mushrooms for psychedelic treatmentMedical mushrooms for psychedelic treatmentinvestingnews.com

Keep reading...Show less

Latest Press Releases

Related News

×